Quintiles and dabl Ltd., a provider of ambulatory blood pressure measurement (ABPM) services, have entered a strategic alliance that expands Quintiles’ suite of cardiovascular safety assessment services. Quintiles’ customers will have access to dabl’s round-the-clock ABPM services with the goal of enhancing the safety and efficacy of global clinical trials.
“dabl’s scientific leadership and data management techniques are setting new industry standards and complement Quintiles’ pioneering cardiac safety solutions,” said Dr. Deepa Desai, executive director, Cardiac Safety Services, Quintiles. “Together we can improve understanding of drug-induced blood pressure responses and help our customers improve trial participant safety, manage risk, and improve efficiency — all vital to meet the challenges of the New Health.”
Professor Eoin O’Brien, medical director of dabl, said, “Accuracy of circadian measurement, speed and excellence in interpreting data have never been more important in the clinical trial process. Biopharma companies will be able to make faster and more confident decisions about the CV effects of their compounds with the combination of Quintiles’ therapeutic expertise and dabl’s proprietary technology and excellence in providing hemodynamic profiles.”